INSILICO MED.C. O.N.

Insilico Medicine has appointed Dr. Halle Zhang as vice president of clinical development for oncology; she will lead the global strategy for the oncology portfolio and report to Dr. Feng Ren. Dr. Zhang brings more than 20 years of experience from roles at Bristol Myers Squibb and other research institutions, with expertise in immuno-oncology, targeted therapies and antibody-drug conjugates. The company highlights progress in its oncology pipeline, including phase I studies for ISM6331 and ISM3412, as well as collaborations with Servier and the Menarini Group. Insilico also points to accelerated drug discovery thanks to AI, solid revenue figures and a low P/E ratio. » More on de.investing.com